Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab and chemotherapy with or without MK-4830 as neoadjuvant treatment for high-grade serous ovarian cancer
2023-505005-16-00Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Jul 2022
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 11
01
Overview
Phase 2, randomised trial in ovarian cancer, primary peritoneal cancer (PPC) and fallopian tube cancer (PFTC) comparing Keytruda + carboplatin + paclitaxel with Keytruda + MK-4830 + carboplatin + paclitaxel (2 arms). Primary endpoint: Change from baseline in circulating tumor deoxyribonucleic acid. Started Jul 2022; status: completed.
02
Drugs
pembrolizumabmk-4830
03
Conditions
ovarian cancerprimary peritoneal cancer (PPC)fallopian tube cancer (PFTC)
Beyond the preview
Go deeper on 2023-505005-16-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505005-16-00.